Archived Insight | January 31, 2018

Spending Law Delays Cadillac Tax and Suspends Other ACA Taxes

On January 22, 2018, President Trump signed into law spending legislation to fund the federal government through February 8, 2018. The law, known as a Continuing Resolution (CR), resulted in the government reopening after a three-day shutdown. The CR delays or suspends two Affordable Care Act taxes that directly affect employer-sponsored plans: the 40 percent excise tax on high-cost plans (the “Cadillac tax”) and the health insurance premium tax. It also suspends the medical device tax.

This Update summarizes the health provisions in the CR and notes the implications for plan sponsors.

Spending Law Delays Cadillac Tax and Suspends Other ACA Taxes

Get the full insight

 

See more insights

Female Nutritionist Holding Image Of Healthy Eating Plate

Health Coaching Enhances Well-Being and Productivity

Your organization can derive significant value from integrating health coaching into its existing health-management programs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

Pharmacist Taking Inventory With Digital Tablet

Executive Order Seeks to Lower Prescription Drug Prices

The order instructs federal departments to issue regulations or work with Congress to identify statutory changes necessary to address drug prices.

Health, Compliance, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

Asian Senior Woman Reading The Information Sheet Of Her Prescribed Medicine

Implications of Medicare Changes for Group Health Plans

Our insight discusses guidance for sponsors of group health plans as well as a chart showing the impact on Medicare Part D cost sharing in 2026.

Compliance, Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.